Full Breakdown
Breakthrough Immunotherapy Trial Shows Zero Recurrence in Three Years
6/1/2026, 8:36:57 PM
NEOPRISM-CRC Trial Results
A UK clinical trial (NEOPRISM-CRC) enrolled 32 patients with stage II or III bowel cancer that were MMR-deficient or MSI-high—a genetic profile present in roughly 10–15 % of UK cases (about 2,000–3,000 diagnoses annually). Participants received three doses of the immunotherapy drug pembrolizumab over nine weeks before surgical resection. Three years after surgery, none of the patients showed disease recurrence.
Background: Immunotherapy and Genetic Subtypes in Bowel Cancer
Immunotherapy, which stimulates the immune system to attack cancer cells, has shown efficacy primarily in tumours with deficient mismatch repair (MMR) or high microsatellite instability (MSI-high). Historically, patients with these subtypes received chemotherapy before surgery. The NEOPRISM-CRC protocol replaces chemotherapy with pre-operative pembrolizumab, aiming to shrink tumours and reduce treatment-related toxicity.
Key Researchers and Clinical Leaders
Data & Statistics
Why It Matters: Potential Shift in Treatment Paradigm
The trial suggests pembrolizumab could become a standard neoadjuvant option for high-risk, genetically defined bowel cancers, potentially eliminating the need for chemotherapy in this subgroup. Researchers also highlight the development of personalised blood tests and immune-profiling tools to identify patients most likely to benefit, supporting a move toward precision oncology.
Official Statements & Responses
Dr Shiu described the findings as “extremely encouraging,” noting that the lack of recurrence “strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers.” Prof Khan emphasized that surgical advances must be paired with deeper insight into tumour biology and genetics to tailor therapy appropriately.
Criticism & Limitations
The benefits apply only to tumours with the MMR-deficient/MSI-high profile. Patients such as Elise Sargent, a 45-year-old with stage IV bowel cancer driven by a different mutation, do not respond to immunotherapy. Sargent and other advocates call for earlier population screening using the FIT (Faecal Immunochemical Test) at age 40 rather than the current threshold of 50, arguing that earlier detection could prevent advanced-stage diagnoses.
On-the-Ground Reports: Patient Experiences
Chris Burston, 73, reported that his tumour “shrank significantly” after pembrolizumab and that post-surgery “the cancer melted away… it completely disappeared.” He reflected that “cancer was basically a death sentence” in his youth, contrasting his current cancer-free status with past expectations.
Conflicting Reports & Gaps
Current evidence does not address long-term outcomes beyond three years, nor does it provide data for patients lacking the targeted genetic mutation. The trial’s size (32 participants) limits statistical power for broader population inference.
Verbatim Quotes
- “Every time I hear a patient has been successfully treated with immunotherapy my heart just leaps,” — Elise Sargent, 45, patient
- “I'm old enough to remember when cancer was basically a death sentence for most people,” — Chris Burston, 73, patient
- “Now we can see you can treat cancer in a way that destroys it and makes people healthy again.” — Chris Burston
- “Seeing that no patients have experienced a cancer recurrence after almost three years of follow-up is extremely encouraging and strengthens our confidence that pembrolizumab is a safe and highly effective treatment to improve outcomes in patients with high-risk bowel cancers,” — Dr Kai-keen Shiu, chief investigator
What’s Next
Researchers aim to secure NHS approval for neoadjuvant pembrolizumab in eligible patients, while parallel advocacy pushes for lowering the FIT screening age to 40. Ongoing studies will evaluate longer-term survival and expand personalised testing to refine patient selection.
